EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Current and emerging approaches to noncompetitive AR inhibition

Christopher M Riley, Jessica M L Elwood, Martyn C Henry iD, Irene Hunter, J Daniel Lopez-Fernandez, Iain J McEwan, Craig Jamieson

Medicinal Research Reviews · 2023-09 · 43 (5) · 1701-1747

DOI: 10.1002/med.21961 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Medicinal Research Reviews, online erschienen am 16.04.2023. Verfasst von Christopher M Riley und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pure and Applied Chemistry, University of Strathclyde, Glasgow, UK. Hauptthemen laut MEDLINE: Receptors, Androgen, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 203 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The androgen receptor (AR) has been shown to be a key determinant in the pathogenesis of castration‐resistant prostate cancer (CRPC). The current standard of care therapies targets the ligand‐binding domain of the receptor and can afford improvements to life expectancy often only in the order of months before resistance occurs. Emerging preclinical and clinical compounds that inhibit receptor activity via differentiated mechanisms of action which are orthogonal to current antiandrogens show promise for overcoming treatment resistance. In this review, we present an authoritative summary of molecules that noncompetitively target the AR. Emerging small molecule strategies for targeting alternative domains of the AR represent a promising area of research that shows significant potential for future therapies. The overall quality of lead candidates in the area of noncompetitive AR inhibition is discussed, and it identifies the key chemotypes and associated properties which are likely to be, or are currently, positioned to be first in human applications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, AndrogenProstatic Neoplasms, Castration-ResistantMaleHumansAndrogen AntagonistsCell Line, Tumor

Stichwörter der Autor:innen

androgen receptordevelopability propertiesnoncompetitive inhibitionprostate cancer

Substanzen

Receptors, AndrogenAndrogen Antagonists

Autor:innen und Institutionen

  • Department of Pure and Applied Chemistry, University of Strathclyde, Glasgow, UK.
  • Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK.

ORCID-Profile: Martyn C Henry

Förderung

  • Medical Research Council

Zitieren

APA

Riley, C. M., Elwood, J. M. L., Henry, M. C., Hunter, I., Daniel Lopez-Fernandez, J., McEwan, I. J., & Jamieson, C. (2023). Current and emerging approaches to noncompetitive AR inhibition. Medicinal Research Reviews, 43(5), 1701-1747. https://doi.org/10.1002/med.21961

Vancouver

Riley CM, Elwood JML, Henry MC, Hunter I, Daniel Lopez-Fernandez J, McEwan IJ, et al. Current and emerging approaches to noncompetitive AR inhibition. Medicinal Research Reviews. 2023;43(5):1701-1747. doi:10.1002/med.21961

BibTeX
@article{Riley2023,
  author = {Riley, Christopher M and Elwood, Jessica M L and Henry, Martyn C and Hunter, Irene and Daniel Lopez-Fernandez, J and McEwan, Iain J and Jamieson, Craig},
  title = {Current and emerging approaches to noncompetitive AR inhibition},
  journal = {Medicinal Research Reviews},
  year = {2023},
  volume = {43},
  number = {5},
  pages = {1701--1747},
  doi = {10.1002/med.21961}
}
Kostenlos starten →